Prolonged Clopidogrel Use After Bare Metal and Drug-Eluting Stent Placement
Open Access
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Interventions
- Vol. 5 (3), 372-380
- https://doi.org/10.1161/circinterventions.111.967257
Abstract
Current guidelines recommend combining clopidogrel with aspirin for up to 1 year after coronary stenting, but the value of clopidogrel beyond this time is uncertain. We evaluated all patients in the Veterans Administration healthcare system receiving either drug-eluting or bare metal stents from 2002 to 2006. The Veterans Administration National Patient Care and Pharmacy databases were used to extract patient characteristics, duration of clopidogrel use, and outcomes for up to 4 years after the index procedure. We used Cox proportional hazards to estimate hazard ratios for death, myocardial infarction, revascularization, and bleeding from a 12-month landmark after stenting that excluded patients with events within the first 12 months. Of 42 254 patients, 29 175 met the study inclusion criteria. Compared with ≤12 months of clopidogrel, prolonged clopidogrel (>12 months) was associated with a lower adjusted risk of death for both drug-eluting stents (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.61, 0.82; P P =0.01) as well as for death and myocardial infarction but was unrelated to stroke or major bleeding. The effect of prolonged clopidogrel on death or myocardial infarction was significantly greater among patients receiving drug-eluting (HR, 0.70; 95% CI, 0.64, 0.84) compared with bare metal stents (HR, 0.88; 95% CI, 0.79, 0.98; interaction P =0.024). Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months. The risk reduction was greater for drug-eluting stents. These data support longer durations of dual antiplatelet therapy for patients receiving a stent, particularly for those receiving a drug-eluting stent.Keywords
This publication has 37 references indexed in Scilit:
- Very Late Stent Thrombosis and Late Target Lesion RevascularizationCirculation, 2012
- Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent ImplantationCirculation, 2012
- Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)The American Journal of Cardiology, 2009
- Stent Thrombosis in SwedenCirculation: Cardiovascular Interventions, 2009
- Drug-Eluting Stent Thrombosis in Routine Clinical PracticeCirculation: Cardiovascular Interventions, 2009
- Safety and Efficacy of Drug-Eluting and Bare Metal StentsCirculation, 2009
- Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical OutcomesCirculation: Cardiovascular Interventions, 2009
- Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal StentsJACC: Cardiovascular Interventions, 2008
- Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS Landmark Trials Data)The American Journal of Cardiology, 2008
- Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular EventsThe American Journal of Cardiology, 2008